Featuring an interview with Prof Patrick Neven, including the following topics:

• Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00)
• Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57)
• Emerging data with novel oral SERD combinations (6:31)
• Challenges for a general medical oncologist in breast cancer (8:41)
• Sequencing and selection of therapies in ER-positive, HER2-negative breast cancer (12:16)
• Evaluating the strategy of switching to an oral SERD during first-line endocrine therapy upon "molecular progression" (23:16)

CME information and select publications